Estamos no ar no ! Saiba mais
18,91 USD
+0,24
1,29%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
18,85
-0,06
0,32%
1 dia
1,29%
5 dias
7,08%
1 mês
6,06%
3 meses
-0,58%
6 meses
8,3%
No acumulado do ano
9,18%
1 ano
34,02%
5 anos
-29,7%
10 anos
-29,7%
 

Sobre: Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

Funcionários: 22.000

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 31%
Neutro 47,6%
Negativo 21,4%
Positivo
WSJ
há 3 dias
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
The European Commission—the EU's executive arm—said that the sale fully addresses officials' earlier concerns that the deal could hinder competition in tampon markets in Czechia, Estonia, and Slovakia.
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
Neutro
PRNewsWire
há 3 dias
Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers
DALLAS, Oct. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today that the requisite number of consents have been received to adopt certain proposed amendments (the "Amendments") with respect to all outstanding notes of Kenvue Inc. (NYSE: KVUE) ("Kenvue"). The results are based on (i) early tenders in the offers to exchange (each an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes (the "Kenvue Notes") issued by Kenvue for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes") and cash and (ii) related consent solicitations (each, a "Consent Solicitation" and, collectively, the "Consent Solicitations") being made by Kimberly-Clark on behalf of Kenvue to adopt the Amendments to the indenture (the "Kenvue Indenture") governing the Kenvue Notes.
Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers
Neutro
24/7 Wall Street
há 8 dias
Market Concentration Is Spooking Wall Street—I'm Buying Kenvue
While nervous investors obsess over a handful of tech giants propping up the whole market, one portfolio manager keeps funneling fresh cash into the brands sitting in every American medicine cabinet, and the reasoning might make you rethink your own
Market Concentration Is Spooking Wall Street—I'm Buying Kenvue
Neutro
Zacks Investment Research
há 10 dias
NWL or KVUE: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Newell Brands (NWL) or Kenvue (KVUE). But which of these two stocks is more attractive to value investors?
NWL or KVUE: Which Is the Better Value Stock Right Now?
Negativo
24/7 Wall Street
há 12 dias
4 Dividend Aristocrats Still Raising Their Payouts No Matter What Their Stock Price Did
One of these stocks lost nearly a fifth of its value over the past year, another nearly doubled, and both still handed shareholders a bigger check. Find out whether the dividends behind these very different charts are built to last.
4 Dividend Aristocrats Still Raising Their Payouts No Matter What Their Stock Price Did
Neutro
PRNewsWire
há 15 dias
Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team
Russ Torres to Depart Kimberly-Clark for External CEO Role Carlos De Jesus to be Appointed as President, North America and Leonardo Curado to be Appointed as President, EMEA After Kenvue Acquisition DALLAS, Oct. 1, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) today announced planned executive transitions and updates to the future leadership team for the company upon completion of its pending acquisition of Kenvue Inc. (NYSE: KVUE), which is expected in the fourth quarter of 2026. Russ Torres, President and Chief Operating Officer of Kimberly-Clark, and Head of the Integration Management Office (IMO), will leave the company to assume an external CEO role.
Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team
Positivo
24/7 Wall Street
há 17 dias
Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?
Kimberly-Clark (NASDAQ:KMB | KMB Price Prediction) pays a quarterly dividend of $1.28 per share. That is an annualized forward rate of $5.12 and a yield of 5.16%.
Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?
Neutro
PRNewsWire
há 18 dias
Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes
DALLAS, Sept. 28, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the commencement, in connection with its previously announced pending acquisition ("Acquisition") of Kenvue Inc. (NYSE: KVUE) ("Kenvue"), of an exchange offer (each an "Exchange Offer" and, collectively, the "Exchange Offers") for any and all outstanding notes (the "Kenvue Notes") issued by Kenvue for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes") and cash.
Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes
Neutro
ETF Trends
há 19 dias
Burning a Hole in My Pocket
I'm talking about the cash I have sitting here that I desperately want to get into the market. Earlier this year, I got a chunk of money from selling a house.
Burning a Hole in My Pocket
Neutro
Reuters
há 23 dias
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
Kimberly-Clark has offered concessions to address EU antitrust concerns about its $40 billion ​bid for Tylenol maker Kenvue , a filing ‌on the European Commission website showed on Wednesday.
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
Gráficos de preços implementados com Lightweight Charts™